More Healthcare Articles

From paused FCPA enforcement to AI-enabled fraud and rising ATA investigations, the global compliance landscape is shifting fast. In this exclusive with CCBJ, a partner at Honigman details the biggest risks ahead—from tariff fallout and supply chain reclassification to the expanding reach of anti-terrorism statutes. National security–linked sectors, including AI, semiconductors, and pharma, should expect increased scrutiny as enforcement priorities evolve.

Read More

Healthcare

TBT: Keeping Up with Healthcare: One Company’s Story

In this #ThrowbackThursday interview from 2018, Sandy Leung, Bristol-Myers Squibb’s EVP & GC, explains how her company is keeping up with changes in healthcare and pharma – and the impact these changes are having on her legal department.

Read More

Healthcare

Time for a Check-Up: the U.S. Healthcare Industry Remains Subject to Aggressive Criminal Antitrust Enforcement

In recent years, participants in U.S. healthcare markets have witnessed aggressive efforts by U.S. authorities to pursue criminal penalties for antitrust violations. That trend appears set to continue: as Acting Assistant Attorney General Richard Powers reiterated during an interview on February 12, 2021, the U.S. Department of Justice Antitrust Division (DOJ) remains focused on investigating and, if appropriate, criminally prosecuting antitrust violations in healthcare industries.

Read More